Huagai Capital
华盖资本
Huagai Capital is a Chinese venture capital firm that appears in elsewhere's corpus primarily as a repeat co-investor alongside major funds in growth-stage deals. It backed Shukun Technology's Series A in 2018 and continued into its 2020 and 2021 rounds alongside Sequoia China and 5Y Capital , joined OrbiMed and Qiming Venture Partners in biotech firm QLT Biotherapeutics' 2026 Series C , and co-led Index Technology's 2024 angel round with Qifu Capital . The pattern suggests a focus on hard-tech and healthcare, though elsewhere's corpus does not contain a direct profile of the firm itself.
AI-generated — may contain errors, please verify.
Coverage
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
五源资本·Yunqi Capital Leads Index Technology's Nearly RMB 100 Million Pre-A Round: Hardware Design Enters Its "Vibe Coding" Moment | Yunqi Capital
What's Happening with AI for Hardware?
云启资本·An AI Company That Wants Ordinary People to "Hard Control" Shenzhen's Electronics Hub Raises Nearly 100 Million Yuan
Another kind of equality.
暗涌Waves·5Y Capital Portfolio Company Shukun Technology Announces New 700 Million Yuan Funding Round | 5Y News
Digital human platforms are penetrating deep into healthcare scenarios.
五源资本·5Y News | Shukun Technology Secures Another 590 Million Yuan in Funding, 5Y Capital Continues Its Support
Shukun Technology Raises Another 590 Million Yuan in Funding, Accelerating Medical AI Value Realization with Triple-Class Certification and Capital Backing
五源资本·
